AF
KDNY

Amalgamated Financial’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Amalgamated Financial’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$77K Buy
+4,705
New +$64K ﹤0.01% 2252

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Amalgamated Financial's KDNY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2022: 4,705 shares worth $77K. The stake represents ﹤0.01% of the portfolio and ranks #2252 among its holdings.

105 funds tracked by Wall St. Rank hold KDNY as of Q1 2022.

  • Amalgamated Financial held 4,705 shares of Chinook Therapeutics, Inc. Common Stock worth $77K as of Q1 2022.
  • Chinook Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2252 holding.
  • 105 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.